Abstract
Familial hyperparathyroidism occurs in a handful of genetic syndromes including Multiple Endocrine Neoplasia (MEN) type 1 and 2A, Familial Hypocalciuric Hypercalcemia (FHH), and Hyperparathyroidism-Jaw Tumor Syndrome (HPT-JT). MEN 1 is characterized by a loss of function in the tumor suppressor gene, Menin, whereas MEN 2 is characterized by a gain of function mutation in the RET proto-oncogene. FHH is characterized by mutations that alter the calcium-sensing receptor in the kidney and parathyroid glands, resulting in mild hypercalcemia and elevated PTH levels. HPT-JT is characterized by hereditary predisposition to jaw tumors and benign and malignant tumors of the parathyroids. All four syndromes are autosomal dominant, with variable penetrance of degree of clinical hyperparathyroidism. Each of these disorders requires careful evaluation, diagnostic testing, genetic analysis, and potentially, surgical management.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Pieterman CR, Schreinemakers JM, Koppeschaar HP, et al. Multiple endocrine neoplasia type 1 (MEN1): its manifestations and effect of genetic screening on clinical outcome. Clin Endocrinol (Oxf). 2009;70(4):575–81. Clinical Investigation; Level 2; Grade B.
Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276(5311):404–7. Basic Science; Level 2; Grade B.
Matkar S, Thiel A, Hua X. Menin: a scaffold protein that controls gene expression and cell signaling. Trends Biochem Sci. 2013;38(8):394–402. Basic Science; Level 2; Grade B.
Dreijerink KM et al. Breast-cancer predisposition in multiple endocrine neoplasia type 1. N Engl J Med. 2014;371(6):583–4. Clinical Review; Level 1; Grade C.
Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990–3011. Clinical Review; Level 2; Grade A-B.
Eller-Vainicher C, Chiodini I, Battista C, et al. Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res. 2009;24(8):1404–10. Clinical Review; Level 2; Grade A-B.
Marx SJ, Menczel J, Campbell G, et al. Heterogeneous size of the parathyroid glands in familial multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf). 1991;35:521–6. Clinical Investigation; Level 2; Grade C.
Rizzoli R, Green 3rd J, Marx SJ. Primary hyperparathyroidism in familial multiple endocrine neoplasia type I. Long-term follow-up of serum calcium levels after parathyroidectomy. Am J Med. 1985;78(3):467–74. Population/Observational Study; Level 3; Grade A-B.
Lairmore TC, Piersall L, DeBenedetti M, et al. Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1). Ann Surg. 2004;239(5):645–47. Clinical Investigation; Level 2; Grade C.
Sugg SL, Krzywda EA, Demeure MJ, et al. Detection of multiple gland primary hyperparathyroidism in the era of minimally invasive parathyroidectomy. Surgery. 2004;136:1303–9. Population/Observational Study; Level 3; Grade A-B.
Wells Jr SA, Famdon JR, Dale JK, et al. Long term evaluation of patients with primary parathyroid hyperplasia managed by total parathyroidectomy and heterotopic autotransplantation. Ann Surg. 1980;192(4):451–8. Population/Observational Study; Level 3; Grade A-B.
Prinz RA, Gamvros OI, Sellu D, et al. Subtotal parathyroidectomy for primary chief cell hyperplasia in the multiple endocrine neoplasia type I syndrome. Ann Surg. 1981;193(1):26–9. Population/Observational Study; Level 3; Grade A-B.
Van Heerden JA, Kent 3rd RB, Sizemore GW, et al. Primary hyperparathyroidism in patients with multiple endocrine neoplasia syndromes: surgical experience. Arch Surg. 1983;118(5):533–6. Population/Observational Study; Level 3; Grade A-B.
Kraimps JL, Duh QY, Demeure M, et al. Hyperparathyroidism in multiple endocrine neoplasia syndrome. Surgery. 1992;112(6):1080–8. Population/Observational Study; Level 3; Grade A-B.
Hellman P, Skogseid B, Juhlin C, et al. Findings and long term results of parathyroid surgery in multiple endocrine neoplasia type 1. World J Surg. 1992;16(4):718–22. Population/Observational Study; Level 3; Grade A-B.
Hellman P, Skogseid B, Oberg K, et al. Primary and reoperative parathyroid operations in hyperparathyroidism of multiple endocrine neoplasia type 1. Surgery. 1998;124(6):993–9. Population/Observational Study; Level 3; Grade A-B.
Dotzenrath C, Cupisti K, Goretzki PE, et al. Long-term biochemical results after operative treatment of primary hyperparathyroidism associated with multiple endocrine neoplasia types I and IIa: is a more or less extended operation essential? Eur J Surg. 2001;167(3):173–8. Population/Observational Study; Level 3; Grade A-B.
Goudet P, Cougard P, Verges B, et al. Hyperparathyroidism in multiple endocrine neoplasia type I: surgical trends and results of a 256-patient series from Groupe D’etude des Neoplasies Endocriniennes Multiples Study Group. World J Surg. 2001;25(7):886–90. Population/Observational Study; Level 3; Grade A.
Arnalsteen LC, Alesina PF, Quiereux JL, et al. Long-term results of less than total parathyroidectomy for hyperparathyroidism in multiple endocrine neoplasia type 1. Surgery. 2002;132(6):1119–24. Population/Observational Study; Level 3; Grade A-B.
Schreinemakers JM, Pieterman CR, Scholten A, et al. The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review. World J Surg. 2011;35(9):1993–2005. Clinical Review; Level 3; Grade A-B.
Tonelli F et al. Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1? Ann Surg. 2007;246(6):1075–82. Population/Observational Study; Level 3; Grade A-B.
Tonelli F, Marcucci T, Fratini G, et al. Surgical approach in patients with hyperparathyroidism in multiple endocrine neoplasia type 1: total versus partial parathyroidectomy. Clinics (Sao Paulo). 2012;67 Suppl 1:155–60. Clinical Review; Level 3; Grade A-B.
Lairmore TC, Govednik CM, Quinn CE, et al. A randomized, prospective trial of operative treatments for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery. 2014;156(6):1326–34. Clinical Investigation; Level 1; Grade B.
Cohen MS, Dilley WG, Wells Jr SA, et al. Long-term functionality of cryopreserved parathyroid autografts: a 13-year prospective analysis. Surgery. 2005;138(6):1033–40. Clinical Investigation; Level 3; Grade A-B.
Wells Jr SA, Asa SL, Dralle H, et al. Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610. Clinical Review; Level 3; Grade A-B.
Maruyama S, Iwashita T, Imai T, et al. Germ line mutations of the ret proto-oncogene in Japanese patients with multiple endocrine neoplasia type 2A and type 2B. Jpn J Cancer Res. 1994;85(9):879–82. Clinical Investigation; Level 2; Grade B.
Raue F, Frank-Raue K, Grauer A. Multiple endocrine neoplasia type 2. Clinical features and screening. Endocrinol Metab Clin North Am. 1994;23(1):137–56. Clinical Review; Level 3; Grade A-B.
Durante C, Romagnoli E, Maranghi M, et al. Hyperparathyroidism in multiple endocrine neoplasia type II A. Clin Cases Miner Bone Metab. 2006;3(2):162–6. Clinical Review; Level 3; Grade A-B.
Skinner MA, Moley JF, Dilley W, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med. 2005;353(11):1105–13. Clinical Investigation; Level 2; Grade B.
Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med. 2003;349(16):1517–25. Clinical Investigation; Level 2; Grade B.
Gagel RF, Tashjian AH, Cummings T, et al. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med. 1988;318(8):478–84. Clinical Investigation; Level 2; Grade A-B.
O’Riordain DS, O’Brien T, Grant CS, et al. Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia types 1 and 2. Surgery. 1993;114(6):1031–7. Population/Observational Study; Level 3; Grade A-B.
Moley JF, Skinner M, Gillanders WE, et al. Management of parathyroid glands during preventive thyroidectomy in patients with multiple endocrine neoplasia type 2. Ann Surg. 2015;262(4):641–6. Clinical Investigation; Level 2; Grade A-B.
Szabó J, Heath B, Hill VM, et al. Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am J Hum Genet. 1995;56(4):944–50. Basic Science; Level 2; Grade A-B.
Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet. Dec 2002;32(4):676–80. Basic Science; Level 2; Grade A.
Marx SJ, Simonds WF, Agarwal SK, et al. Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res. 2002;17 Suppl 2:N37–43. Clinical Review; Level 3; Grade A-B.
Masi G, Barzon L, Iacobone M, et al. Clinical, genetic and histopathologic investigation of CDC73-related familial hyperparathyroidism. Endocr Relat Cancer. 2008;15(4):1115–26. Basic Science; Level 2; Grade B.
Hannan FM, Nesbit MA, Christie PT, et al. Familial isolated primary hyperparathyroidism caused by mutations of the MEN1 gene. Nat Clin Pract Endocrinol Metab. 2008;4(1):53–8. Clinical Investigation; Level 4.
Thakker RV. Genetics of endocrine and metabolic disorders: parathyroid. Rev Endocr Metab Disord. 2004;5(1):37–51. Clinical Review; Level 3; Grade A-B.
Jackson CE. Hereditary hyperparathyroidms associated with recurrent pancreatitis. Ann Intern Med. 1958;49(4):829–36. Clinical Investigation; Level 4.
Pavlovic S, Valyi-Nagy T, Profirovic J, David O. Fine-needle aspiration of brown tumor of bone: cytologic features with radiologic and histologic correlation. Diagn Cytopathol. 2009;37(2):136–9. Clinical Investigation; Level 2; Grade A-B.
Teh BT, Farnebo F, Kristoffersson U, et al. Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of wild type allele in renal hamartomas. J Clin Endocrinol Metab. 1996;81(12):4204–11. Clinical Investigation; Level 2; Grade A-B.
Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med. 2000;343(25):1863–75. Clinical Review; Level 3; Grade A-B.
Sharretts JM, Simonds WF. Clinical and molecular genetics of parathyroid neoplasms. Best Pract Res Clin Endocrinol Metab. 2010;24(3):491–502. Clinical Review; Level 3; Grade A-B.
Shattuck TM, Välimäki S, Obara T, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003;349(18):1722–9. Clinical Review; Level 3; Grade A-B.
Cetani F, Pardi E, Borsari S, et al. Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab. 2004;89(11):5583–91. Clinical Investigation; Level 2; Grade A-B.
Tan MH, Teh BT. Renal neoplasia in the hyperparathyroidism-jaw tumor syndrome. Curr Mol Med. 2004;4(8):895–7. Clinical Investigation; Level 4.
Bradley KJ, Hobbs MR, Buley ID, et al. Uterine tumors are a phenotypic manifestation of hyperparathyroidism-jaw tumour syndrome. J Intern Med. 2005;257(1):18–26. Clinical Review; Level 3; Grade A-B.
Carling T, Udelsman R. Parathyroid tumors. Curr Treat Options Oncol. 2003;4(4):319–28. Clinical Review; Level 3; Grade A-B.
Sarquis MS, Silveira LG, Pimenta FJ, et al. Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. Surgery. 2008;143(5):630–40. Clinical Investigation; Level 2; Grade B.
Christensen SE, Nissen PH, Vestergaard P, Mosekilde L. Familial hypocalciuric hypercalcaemia: a review. Curr Opin Endocrinol Diabetes Obes. 2011;18(6):359–70. Clinical Review; Level 3; Grade A-B.
Heath 3rd H, Jackson CE, Otterud B, Leppert MF. Genetic linkage analysis in familial benign (hypocalciuric) hypercalcemia: evidence for locus heterogeneity. Am J Hum Genet. 1993;53(1):193–200. Basic Science; Level 2; Grade B.
Lloyd SE, Pannett AA, Dixon PH, Whyte MP, Thakker RV. Localization of familial benign hypercalcemia, Oklahoma variant (FBHOk), to chromosome 19q13. Am J Hum Genet. 1999;64(1):189–95. Basic Science; Level 2; Grade B.
Brown EM, Hebert SC. Calcium-receptor-regulated parathyroid and renal function. Bone. 1997;20(4):303–9. Clinical Review; Level 3; Grade A-B.
Brown EM. Clinical lessons from the calcium-sensing receptor. Nat Clin Pract Endocrinol Metab. 2007;3(2):122–33. Clinical Review; Level 3; Grade A-B.
Heath 3rd H. Familial benign (hypocalciuric) hypercalcaemia: a troublesome mimic of mild primary hyperparathyroidism. Endocrinol Metab Clin North Am. 1989;18(3):723–40. Clinical Investigation; Level 3; Grade A-B.
Law Jr WM, Heath 3rd H. Familial benign hypercalcaemia (hypocalciuric hypercalcaemia): clinical and pathogenetic studies in 21 families. Ann Intern Med. 1985;102:511–9. Clinical Investigation; Level 3; Grade A-B.
Pasieka JL, Andersen MA, Hanley DA. Familial benign hypercalcaemia: hypercalciuria and hypocalciuria in affected members of a small kindred. Clin Endocrinol (Oxf). 1990;33(4):429–33. Clinical Investigation; Level 3; Grade A-B.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
De Silva, G.S., Lairmore, T.C., Moley, J.F. (2017). Familial Hyperparathyroidism: Multiple Endocrine Neoplasia Types II and I; Familial Hypocalciuric Hypercalcemia; Hyperparathyroidism-Jaw Tumor Syndrome. In: Stack, Jr., B., Bodenner, D. (eds) Medical and Surgical Treatment of Parathyroid Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-26794-4_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-26794-4_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-26792-0
Online ISBN: 978-3-319-26794-4
eBook Packages: MedicineMedicine (R0)